← Latest news 
Khorakiwala Saves Wockhardt From Default Now One Antibiotic Could Rewrite His Legacy
Business
Published on 24 April 2026
The rescue hinged on one antibiotic breakthrough
Habil Khorakiwala’s turnaround of Wockhardt began amid near bankruptcy, including payment defaults to bondholders and troubled manufacturing units. After surviving the company’s worst crises, the focus has shifted to a single blockbuster antibiotic drug hailed as the biggest breakthrough after penicillin. If it scales, Khorakiwala could re-enter the top league again.
- Khorakiwala navigated Wockhardt through payment and factory turmoil
- Bondholder defaults marked the firm’s deepest crisis
- A single antibiotic drug is now seen as the potential game-changer
- Success could restore Khorakiwala’s standing in pharma
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times